Strategic partnership Navega Therapeutics has recently partnered with Charles River Laboratories for an AAV9 production program, indicating openness to collaboration with contract manufacturers and potential access points for scaling production and downstream services.

Clinical and regulatory signals With ongoing activity in early-stage development and recognition through NIH and TechConnect awards, there may be opportunities to engage on grant-driven funding support, translational studies, or advisory services to accelerate development timelines.

Specialized expertise needs As a small, high-innovation biotech (2–10 employees) focused on epigenetic gene therapies for chronic pain, Navega may benefit from specialized CROs, device and delivery partners, and regulatory consultants with pain-management and gene-therapy experience.

Funding and growth With revenue in the low-to-mid single digits and total funding around $12M, Navega could be exploring strategic investors or collaboration deals to expand IND-enabling studies, manufacturing scale, or platform expansion into related indications.

Technology and data needs Their tech stack and rapid growth focus suggest opportunities for data analytics, digital engagement platforms, and specialized bioinformatics or cloud-based collaboration tools to support preclinical data management, remote monitoring, and partner communications.